Results 131 to 140 of about 599,368 (371)
Brain Pathology, Volume 33, Issue 1, January 2023., 2023 There is no pharmacological treatment available to limit progressing neuronal death after cerebral ischemia. Here we show that targeting the interaction of GABAB receptors with CaMKII using a synthetic interfering peptide after an excitotoxic insult in cultured neurons or in brain slices from MCAO‐treated mice restored downregulated GABAB receptor ...
Karthik Balakrishnan +7 more
wiley +1 more source
Oman Medical Journal, 2013 Objectives: This study was aimed to determine plasma levels of total (TFPI-T) and free (TFPI-F) tissue factor pathway inhibitor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) in a cohort of Saudi patients with chronic
Syed Shahid Habib
doaj +1 more source
Stroke, 2012 Background and Purpose— There are few validated models for prediction of risk of symptomatic intracranial hemorrhage (sICH) after intravenous tissue-type plasminogen activator treatment for ischemic stroke.
B. Menon +10 more
semanticscholar +1 more source
BMEMat, EarlyView.This review highlights the complex roles of cellular senescence in cancer progression and suppression, discusses the mechanisms and regulatory pathways involved, and evaluates the efficacy of the “One‐Two punch” sequential treatment approach while addressing emerging challenges in this novel therapeutic strategy.
Qiuming Pan +12 more
wiley +1 more source
Рациональная фармакотерапия в кардиологии, 2016 Possibilities to use and advantages of a new tissue plasminogen activator (tenekteplase) in patients with acute coronary syndrome (ACS) with ST segment elevation are discussed.
N. A. Novikova, A. E. Udovichenko
doaj +1 more source
Effect of dsRNA on Mesangial Cell Synthesis of Plasminogen Activator Inhibitor Type 1 and Tissue Plasminogen Activator [PDF]
, 2009 Background/Aims: Viral infections are a major problem worldwide and many of them are complicated by virally induced glomerulonephritides. Progression of kidney disease to renal failure is mainly attributed to the development of renal fibrosis ...
Merkle, Monika +4 more
core +1 more source
Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
New England Journal of Medicine, 2011 BACKGROUND The effectiveness of various solutions instilled into the central venous catheter lumens after each hemodialysis session (catheter locking solutions) to decrease the risk of catheter malfunction and bacteremia in patients undergoing ...
B. Hemmelgarn +10 more
semanticscholar +1 more source
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA [PDF]
, 2009 HGF (hepatocyte growth factor) is a pleiotropic cytokine homologous to the serine protease zymogen plasminogen that requires canonical proteolytic cleavage to gain functional activity.
Andrew M. Schumacher +47 more
core +3 more sources
Plasminogen Activator Inhibitor Type‐1 as a Regulator of Fibrosis
Journal of Cellular Biochemistry, 2018 Fibrosis is known as a frequent and irreversible pathological condition which is associated with organ failure. Tissue fibrosis is a central process in a variety of chronic progressive diseases such as diabetes, hypertension, and persistent inflammation.
Reyhaneh Rabieian +5 more
semanticscholar +1 more source
Contemporary Perspectives on Chronic Renal Disorders
Chronic Diseases and Translational Medicine, EarlyView.ABSTRACT The prevalence of renal diseases and its associated burden on healthcare have tremendously risen in the past few years. From simple markers assessing kidney function, current renal research delves into understanding the diseases at the cellular and molecular levels and not just at treating, but at improving quality of life, arresting ...
Deenadhayalan Ashok +5 more
wiley +1 more source